PB1202 Fibrinogen Concentration and Plasma Clot Properties as Predictors of Cardiovascular Disease Mortality in Black South Africans

ISTH Academy, Faculty / Presenters, 406830

PB1203 The Influence of Human Immunodeficiency Virus Infection and Antiretroviral Therapy on Plasma Clot Properties in a Group of Black South African Women

ISTH Academy, Faculty / Presenters, 406831

PB1201 Update on the Proposed Standardized Method for Scanning Electron Microscopy Analysis of Fibrin Clots

ISTH Academy, Faculty / Presenters, 406832

PB1200 Evaluation of the Association of Factor XIII at Hospital Arrival and Outcomes in a Cohort of Severely Injured Patients

ISTH Academy, Faculty / Presenters, 406833

PB1195 Biochemical and Structural Regulation of the Enzymatic Degradation of Blood Clots

ISTH Academy, Faculty / Presenters, 406834

PB1196 In Vitro Comparisons of Two Fibrinogen Concentrates on Fibrin Clot Properties in Dysfibrinogenemia

ISTH Academy, Faculty / Presenters, 406835

PB1197 Neutrophil Serine Proteases Cleave Fibrinogen to Alter Fibrin Clot Structure

ISTH Academy, Faculty / Presenters, 406836

PB1193 Acute Myocardial Infarction Thrombi Show Fibrin Film that Increases with Ischaemia Duration

ISTH Academy, Faculty / Presenters, 406837

PB1198 Retrospective Genotypic Data Analysis of Patients with Suspected Hereditary Fibrinogen Deficiency

ISTH Academy, Faculty / Presenters, 406838

PB1214 Characterization of Dynamic Changes to Fibrinolysis in Porcine Model of Cardiac Arrest

ISTH Academy, Faculty / Presenters, 406839

PB1212 Effect of PAI-1 on Clot Structure and Fibrinolysis

ISTH Academy, Faculty / Presenters, 406840

PB1213 The Development of a Mini-Scale Euglobulin Clot Lysis Assay

ISTH Academy, Faculty / Presenters, 406841

PB1210 Incorporation of a2-Plasmin Inhibitor into Plasma Clots of Patients with Venous Thrombosis

ISTH Academy, Faculty / Presenters, 406842

PB1211 Individual Determination of the Components of the Fibrinolytic System in Platelet-Depleted Plasma and Derived Euglobulin Fraction

ISTH Academy, Faculty / Presenters, 406843

PB1209 Thrombo-Inflammatory and Fibrinolytic Deficit Biomarkers and their Relationship with Circulating Glycosaminoglycans in End-Stage Renal Disease Patients

ISTH Academy, Faculty / Presenters, 406844

PB1208 Thrombin Activatable Fibrinolysis Inhibitor Dependent Effects on Whole Blood Clot Formation and Lysis Dynamics Across the Peripartum Period

ISTH Academy, Faculty / Presenters, 406845

PB1206 Plasmin Generation is Impaired in Patients with Bleeding Disorders of Unknown Cause

ISTH Academy, Faculty / Presenters, 406846

PB1217 The Contribution of Plasmin(ogen) Receptors to Neuroinflammation in a Murine Model of MS

ISTH Academy, Faculty / Presenters, 406847

PB1224 Cell-Lysis (Lysozyme) Activity in Japanese Fermented Food-Natto

ISTH Academy, Faculty / Presenters, 406848

PB1220 DNase-1 Overcomes Thrombolytic rT-PA Resistance of Platelet-Rich Ischemic Stroke Thrombi

ISTH Academy, Faculty / Presenters, 406849

PB1223 EkoSonic Endovascular System Promotes Thrombolysis by Altering Fibrin Fibre Thickness

ISTH Academy, Faculty / Presenters, 406850

PB1221 Prospective Study Comparing Point-of-Care Viscoelastic Testing and Standard Laboratory Testing for the Prediction of Bleeding Complications in Patients after Systemic Thrombolysis Therapy

ISTH Academy, Faculty / Presenters, 406851

PB1222 ROTEM-Identified Hyperfibrinolysis does not Correlate with Poor Outcomes in Large Vessel Occlusion Stroke

ISTH Academy, Faculty / Presenters, 406852

PB1219 Structure-Function Studies on the Serine Protease Domain of Factor VII Activating Protease (FSAP) to Characterize its Interaction with Substrates and Inhibitors

ISTH Academy, Faculty / Presenters, 406853

PB1218 Aptamer Inhibitor of Von Willebrand Factor Induces Thrombolysis and Improves Vascular Patency Upon Immediate and Delayed Treatment in a Microfluidic Model of Stroke

ISTH Academy, Faculty / Presenters, 406854

PB1233 A Single-Center Study of Reduced-Dose Corticosteroids Therapy for Patients with Acquired Hemophilia A

ISTH Academy, Faculty / Presenters, 406855

PB1235 Acquired Hemophilia A in Very Old Patients: Issues on Therapy Choice. A Case Report

ISTH Academy, Faculty / Presenters, 406856

PB1234 Prevalence of Studies with Acquired von Willebrand Syndrome Laboratory Profile at the Hospital Italiano de Buenos Aires (HIBA)

ISTH Academy, Faculty / Presenters, 406857

PB1229 Haemostatic Control with Recombinant Porcine Factor VIII in Acquired Haemophilia A

ISTH Academy, Faculty / Presenters, 406858

PB1230 Single Centre Review of Practice for Treatment of Acquired Haemophilia A Patients

ISTH Academy, Faculty / Presenters, 406859

PB1228 Inhibitor Detection in Acquired Hemophilia A: A Comparison between the Nijmegen Modified Bethesda Assay and an Anti-FVIII ELISA

ISTH Academy, Faculty / Presenters, 406860

PB1227 Lupus Anticoagulant in Acquired Hemophilia A Subjects in Quebec: Data from the Quebec Reference Center for Inhibitors

ISTH Academy, Faculty / Presenters, 406861

PB1226 Acquired Haemophilia A in Finland: A Nationwide Study of Incidence, Treatment and Outcomes

ISTH Academy, Faculty / Presenters, 406862

PB1225 Acquired Haemophilia in the COVID-19 Pandemic Era - Does Vaccination or Infection Increase its Risk and Influence Outcomes?

ISTH Academy, Faculty / Presenters, 406863

PB0617 Kinetics of Clot Formation and Fibrinolysis in Severely Injured Trauma Patients

ISTH Academy, Faculty / Presenters, 406864

PB0616 UK National External Quality Assessment Scheme for Blood Coagulation (UK NEQAS BC) Evaluation of the Point of Care Fibrinogen Device

ISTH Academy, Faculty / Presenters, 406865

PB0614 Use of a Microfluidic Model to Evaluate Platelet Function in Traumatic Brain Injury Patients Pre- and Post- Platelet Transfusion

ISTH Academy, Faculty / Presenters, 406866

PB0177 An Examination of Access to Preventive Therapies for Persons with Hemophilia (PWH): A Pilot Survey on Behalf of the International Prophylaxis Study Group (IPSG)

ISTH Academy, Faculty / Presenters, 406867

PB0178 Factor X Enhances the Coagulant Potentials of Emicizumab

ISTH Academy, Faculty / Presenters, 406868

PB0174 Half-Life of Factor VIII in an Adult and Pediatric Population: Study at 03 Centers in Western Algeria

ISTH Academy, Faculty / Presenters, 406869

PB0175 Impact of Reagent on the Estimation of Eloctate and Adynovate Pharmacokinetic (PK) Parameters?

ISTH Academy, Faculty / Presenters, 406870

PB0176 Laboratory Monitoring of Severe Hemophilia Patients during PK at the Hemowab Reference Center: A Retrospective Study

ISTH Academy, Faculty / Presenters, 406871

PB0170 Evaluation of the Extended-Half Life FVIII Products' Measurement Accuracy and Precision With Five Different Types of Laboratory Assays

ISTH Academy, Faculty / Presenters, 406872

PB0173 Coagulation Assay Discrepancies for Factor IX Activity in Hemophilia B

ISTH Academy, Faculty / Presenters, 406873

PB0171 Polymorphisms in MAPk9 and CSF1R Associated with Immune Regulatory Gene and their Impact on Inhibitor Development in Patients with Hemophilia A

ISTH Academy, Faculty / Presenters, 406874

PB0172 Thrombodynamics: A Novel Assay for Diagnostic Evaluation of Haemophilia A Patients

ISTH Academy, Faculty / Presenters, 406875

PB0167 De Novo Intron 22 Inversion Carrier Detection - The Emerging Value of Genetic Analysis in a Devloping Country

ISTH Academy, Faculty / Presenters, 406876

PB0168 In Vitro Assessment of Clinical Coagulation Assays in the Presence of Concizumab

ISTH Academy, Faculty / Presenters, 406877

PB0169 Unearthing the Genotype-Inhibitor Phenotype Association in Severe Hemophilia A: A North Indian Cohort Study

ISTH Academy, Faculty / Presenters, 406878

PB0166 Liver Directed Gene Therapy in Hemophilia A Mice is Dependent on Notch Pathway Driven Endothelial Development

ISTH Academy, Faculty / Presenters, 406879

PB0163 Differential Binding of Recombinant FVIII Products to Platelets, and Impact of FVIII on VWF Expression and Platelet Contractility In Vitro

ISTH Academy, Faculty / Presenters, 406880

PB0164 Full Characterization of Three F8 Deletions Causing Severe Hemophilia A with High Responding FVIII Inhibitors may be Associated with the Mechanism of Microhomology-Mediated Break-Induced Replication

ISTH Academy, Faculty / Presenters, 406881

PB0165 Gene Correction of Human Hemophilia B Mutation by PAM-Flexible Cas9-Mediated Base-Editing Approach

ISTH Academy, Faculty / Presenters, 406882

PB0157 In Vitro Thrombin Generation in the Presence of Emicizumab Sequence Identical Analogue (emi-SIA) and Concizumab

ISTH Academy, Faculty / Presenters, 406883

PB0158 Preanalytical Quenching of FVIII Using FVIII-Inhibitors Improves the Specificity of Functional Emicizumab Testing

ISTH Academy, Faculty / Presenters, 406884

PB0159 Relative Role of Auxiliary Plasma Protease Inhibitors in Thrombin Inhibition at Reduced Antithrombin Levels

ISTH Academy, Faculty / Presenters, 406885

PB0160 The Impact of Past Inhibitor on Health Status in Patients with Haemophilia a in The Netherlands

ISTH Academy, Faculty / Presenters, 406886

PB0161 The Potential Role of Matrix Metalloproteinases in the Onset of Haemophilic Arthropathy

ISTH Academy, Faculty / Presenters, 406887

PB0154 Blood-Induced Inflammation in Hemophilia is Associated with Impaired Macrophage Function

ISTH Academy, Faculty / Presenters, 406888

PB0155 Characterization of Zebrafish F8 Mutant and Modeling Hemophilia A

ISTH Academy, Faculty / Presenters, 406889

PB0156 Higher Thrombin Generation is Predicted when Switching Directly from Emicizumab to Mim8 in Patients with Hemophilia A

ISTH Academy, Faculty / Presenters, 406890

PB0153 Evaluation of Cell Type-Specificity of Native Enhancer Elements from the F8 Locus

ISTH Academy, Faculty / Presenters, 406891

PB0150 Fibrin Clot Formation is a Reliable Biological Marker to Evaluate FVIII Replacement Therapy in Hemophilia A Patients

ISTH Academy, Faculty / Presenters, 406892

PB0151 The Effect of Single and Combined Knockouts of GABARAPs Proteins Family on FVIII Intracellular Localization and Secretion

ISTH Academy, Faculty / Presenters, 406893

PB0152 The Spectrum of FVIII-Specific Antibodies in Persons with Hemophilia A: A Cross-Sectional Nationwide Population Study

ISTH Academy, Faculty / Presenters, 406894

PB0145 Extra-Hemostatic Roles of FVIII in Musculoskeletal System in a FVIII Knockout Mice Model

ISTH Academy, Faculty / Presenters, 406895

PB0146 Functional Characterization of a Human F9 Gene-Inserted Product in Hemophilia B Mice

ISTH Academy, Faculty / Presenters, 406896

PB0147 FVIII/Anti-FVIII Immune Complexes Prevent FVIII-Specific Activation of B Cells in a Hemophilia A Mouse Model

ISTH Academy, Faculty / Presenters, 406897

PB0143 Induced B Cell Tolerance in Hemophilia A Mice is Destroyed by Infections

ISTH Academy, Faculty / Presenters, 406898

PB0142 FVIII-Containing Immune Complexes Interrupt Platelet Aggregation in an Ex-Vivo Model of Primary Hemostasis

ISTH Academy, Faculty / Presenters, 406899

PB1303 A Study of Support for Hemophilia Patients Using the “ Questionnaire for Daily Movement and Sensory of PwH”

ISTH Academy, Faculty / Presenters, 406900

PB1304 Development of a Multidisciplinary Bleeding Disorder Committee in a Reference Hospital

ISTH Academy, Faculty / Presenters, 406901

PB1306 Inhibitor Recurrence Following Immune Tolerance Induction in a Hemophilia A Patient with Inhibitor Post COVID-19 Infection

ISTH Academy, Faculty / Presenters, 406902

PB1307 Management of Severe Hemophilia A Patients: Low-Dose Prophylaxis vs On- Demand Treatment

ISTH Academy, Faculty / Presenters, 406903

PB1308 Successful Hip Arthroplasty in a Patient with Combined Factor V and Factor FVIII Deficiency

ISTH Academy, Faculty / Presenters, 406904

PB1309 Switching from Factor VIIa to Emicizumab in Patients with Hemophilia A and Inhibitor (HAI) in Korea

ISTH Academy, Faculty / Presenters, 406905

PB1300 Intramural Hematoma of Gastrointestinal Tract in People With Hemophilia: A Pooled Study

ISTH Academy, Faculty / Presenters, 406906

PB1301 Low-Titer Inhibitor and Decreased FVIII Activity to 1.1% with Increased Bleeding in a 4 Year Old Patient with Congenital Mild Hemophilia A

ISTH Academy, Faculty / Presenters, 406907

PB1297 A UK Single Centre Experience of Switching Adolescents with Severe Haemophilia A to Turoctocog Alfa Pegol

ISTH Academy, Faculty / Presenters, 406908

PB1299 Obstetrical Decision-Making in Moderate or Severe Hemophilia A and B: A Qualitative Study Exploring Parents' Experiences, Preferences and Needs

ISTH Academy, Faculty / Presenters, 406909

PB1294 First Reported Case of Cardiac Surgery in A Patient with Hemophilia B on Treatment with Albutrepenonacog Alfa (rIX-FP)

ISTH Academy, Faculty / Presenters, 406910

PB1296 A Prospective, Non-Interventional Study to Investigate the Effectiveness of rVIII-SingleChain in Patients with Hemophilia A

ISTH Academy, Faculty / Presenters, 406911

PB1291 Joint Range of Motion Findings Among Female Patients with Hemophilia A from the ATHNdataset

ISTH Academy, Faculty / Presenters, 406912

PB1292 Rationale and Design of PathfinderReal: A Prospective, Non- Interventional Study Assessing Joint Health in Adults With Haemophilia A after Switching to Prophylaxis with Turoctocog Alpha Pegol (N8-GP)

ISTH Academy, Faculty / Presenters, 406913

PB1285 A Novel Mutation of Haemophilia C in a Kindred: a F11 Splice Site Variant

ISTH Academy, Faculty / Presenters, 406914

PB1286 Cardiac Surgery in a Patient with Severe Haemophilia A Receiving Emicizumab Prophylaxis - A Case Report

ISTH Academy, Faculty / Presenters, 406915

PB1287 Efficacy of Florio Haemo in Improving Health-Related Quality of Life and Treatment Adherence in Patients with Hemophilia

ISTH Academy, Faculty / Presenters, 406916

PB1288 Immune Tolerance Induction (ITI) Strategies in Haemophilia A Patients with Inhibitors - Data from the MOTIVATE Study

ISTH Academy, Faculty / Presenters, 406917

PB1289 Real-World Data of Hemophilia A with Inhibitor Patients Using Emicizumab - 1st Report in Korea

ISTH Academy, Faculty / Presenters, 406918

PB1290 Successful Very Low Dose Immune Tolerance Induction with Albutrepenonacog Alfa in a Severe Hemophilia B Child with Anaphylactic Reaction to Factor IX

ISTH Academy, Faculty / Presenters, 406919

PB1279 E- Health Applications on Hemophilia Patients: Review and Experience in a Reference Hospital in Spain

ISTH Academy, Faculty / Presenters, 406920

PB1280 Excellent Real World Experience using Damoctocog Alfa Pegol

ISTH Academy, Faculty / Presenters, 406921

PB1281 Natural History of Hepatitis C Virus (HCV) Infection in Korean Hemophilic Cohort

ISTH Academy, Faculty / Presenters, 406922

PB1265 “HERMES” - HEmophilia Related MEntal illnesS: A Cross-Sectional, Multicenter Study in Switzerland

ISTH Academy, Faculty / Presenters, 406923

PB1282 Real-World Unmet Needs of Adult Patients with Severe Hemophilia A without Inhibitors in Poland: How to Select the Optimal Therapy?

ISTH Academy, Faculty / Presenters, 406924

PB1268 Clinical Outcomes with Octocog Alfa in Patients with Hemophilia A in China: 1-year of Follow-up of the AHEAD International Study

ISTH Academy, Faculty / Presenters, 406925

PB1269 Comorbidities - An Additional Burden in the Real Life of Patients with Haemophilia

ISTH Academy, Faculty / Presenters, 406926

PB1270 Hematopoietic Stem Cell Transplantation in a Newborn Suffering from Severe Combined Immunodeficiency and Severe Hemophilia A

ISTH Academy, Faculty / Presenters, 406927

PB1272 Impact of the Difference in the Cutoff Point of the Values of Clotting Factors VIII and IX in the Definition of Women with Hemophilia and Hemophilia Carrier

ISTH Academy, Faculty / Presenters, 406928

PB1273 Inhibitor Recurrence on Emicizumab Prophylaxis in Tolerized Patients with Severe Hemophilia A

ISTH Academy, Faculty / Presenters, 406929